We chose PRAME as the most prominent cancer–testis antigen in AML.19, 20 CMVpp65 as a very abundant and immunogenic viral antigen was added for loading of a third batch of DCs, allowing us to differentiate between the induction of primary and secondary immune responses by comparison of CMV‐seronegative and CMV‐seropositive patients. The gene discussed is PRAME; the disease is cancer.